Requires health practitioners to discuss with patients the risks associated with certain pain medications before prescribing such medications; requires that for the first opioid analgesic prescription of a calendar year the prescribing physician shall counsel the patient on the risks of overdose.
Summary
Bill A03116 amends the public health law to require health practitioners to engage in discussions with patients regarding the risks associated with opioid prescriptions. Specifically, practitioners must inform patients about the dangers of addiction, overdose, and the potential for dependence on these medications before issuing an initial prescription and again prior to the third prescription in a treatment course. Additionally, for the first opioid analgesic prescription exceeding a one-week supply in a calendar year, practitioners are mandated to counsel patients on overdose risks and inform them about the availability of opioid antagonists, such as naloxone.
Impact
The bill aims to enhance patient safety by ensuring that individuals receiving opioid prescriptions are well-informed about the associated risks. This could lead to a reduction in opioid misuse and overdose incidents within the state. By mandating these discussions, the bill also seeks to promote alternative treatment options and ensure that patients are aware of the potential dangers of mixing opioids with other substances. The implementation of this law may require updates to existing medical guidelines and training for healthcare providers.
Sentiment
The general sentiment surrounding Bill A03116 appears to be supportive, as it addresses a critical public health issue related to opioid prescriptions and the opioid crisis. Stakeholders, including health practitioners and patient advocates, recognize the importance of informed consent and the need for better communication regarding the risks of opioid medications. However, there may be concerns about the feasibility of implementing these requirements in practice, particularly in busy clinical settings.
Contention
Notable points of contention may arise regarding the practicality of enforcing these discussions in a timely manner during patient visits, especially in light of the increasing patient load on healthcare providers. Some practitioners may express concerns about the additional burden this places on their practice, while advocates for patient safety may argue that these discussions are essential for preventing opioid misuse and protecting public health. There may also be differing opinions on the adequacy of the guidelines to be developed by the department for these discussions.
Same As
Requires health practitioners to discuss with patients the risks associated with certain pain medications before prescribing such medications; requires that for the first opioid analgesic prescription of a calendar year the prescribing physician shall counsel the patient on the risks of overdose.
Requires health practitioners to discuss with patients the risks associated with certain pain medications before prescribing such medications; requires that for the first opioid analgesic prescription of a calendar year the prescribing physician shall counsel the patient on the risks of overdose.
Requires health practitioners to discuss with patients the risks associated with certain pain medications before prescribing such medications; requires that for the first opioid analgesic prescription of a calendar year the prescribing physician shall counsel the patient on the risks of overdose.
Requires health practitioners to discuss with patients the risks associated with certain pain medications before prescribing such medications; requires that for the first opioid analgesic prescription of a calendar year the prescribing physician shall counsel the patient on the risks of overdose.
Requires practitioners to discuss certain risks with a patient who is being prescribed a schedule II controlled substance or an opioid analgesic; requires the department of health to develop practitioner guidelines.
Requires practitioners to discuss certain risks with a patient who is being prescribed a schedule II controlled substance or an opioid analgesic; requires the department of health to develop practitioner guidelines.
Requires health care practitioners prescribing opioid medications to limit amount of prescribed medication to seven-day supply, except in certain circumstances.
Requires practitioners to provide counselling to patients about the potential addictive properties of opioids prior to prescribing such medications; requires pharmacists to provide counselling to patients about the potential addictive properties of opioids at the time a prescription for opioids is filled.